Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)

Next Previous
Trial Profile

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nemtabrutinib (Primary) ; Zilovertamab vedotin (Primary)
  • Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Richter's syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms waveLINE-006
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 18 Apr 2025 Planned End Date changed from 26 Apr 2027 to 17 May 2029.
  • 21 Nov 2024 According to a Merck and Co media release, first results from cohort C as well as Cohort A of this study, for patients with relapsed or refractory mantle cell lymphoma, will be presented in different poster sessions, at the 2024 ASH Annual Meeting and Exposition in San Diego from Dec. 7-10.
  • 18 Nov 2024 Protocol was amended Cohort D is closed to enrollment of participants with CLL and enrollment of participants into Arm 2 (zilovertamab vedotin at Dose 2 on Days 1 & 8 of each 3 Week Cycle (Q2/3W)). Treatment arms changed from 6 to 5 and hence there was a change in primary endpoints and patient number.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top